The pharmaceutical composition applied to the treatment of diabetes, and reduces the frequency of injecting medicine and helps stabilize the blood concentration of the patients, meanwhile, the adaptability is increased too.巍蔡
and extracts of flavonoids from mulberry leaves,ginkgo bilobaextract compound, bitter melon extract and tea polyphenol extract and the like are on sale in the market, such as by Hunan Geneham Biomedical Technology Ltd., Shaoguan Jumin Pharmaceutical Co., Ltd., and other medicine and extract manufa...
Nolan et al., "Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone," The New England Journal of Medicine, vol. 331, pp. 1188-1193 (Nov. 1994). Ciaraldi et al., "In Vitro Studies on the Action of CS-045, a New Antidiabetic Agent," Meta...
Medicine composition for treating diabetesA synergistic medicine containing gliclazide and the extracts of Chinese-medicinal materials and its application in preparing the medicines for treating diabetes are disclosed.胡可丁
FIELD: medicine, pharmacy.;SUBSTANCE: invention relates to a pharmaceutical composition made mainly as solid medicinal formulations and comprising therapeutically effective amount of gliclazide and the special additive in the amount 4.65-6.70 mass. p. per mass unit of active substance. The additive ...
FIELD: medicine, endocrinology, pharmacy. SUBSTANCE: invention relates to medicinal preparation with an antidiabetic effect. Invention proposes the pharmaceutical composition with an antidiabetic effect containing effective dose of gliclazide and saccharide, microcrystalline cellulose, starch, hydroxypropylmethyl...
25, 2016 under International Publication No. WO 2016/131414 A1, and the disclosure of which is incorporated herein by reference.FIELD OF THE INVENTIONThe present invention belongs to the field of medicine. In particular, the present invention relates to novel deuterated chenodeoxycholic acid ...
Y. Iwamoto et al., “Effect of combination therapy of troglitazone and sutphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone,” Diabetic Medicine, 1996, vol. 13, pp. 365-370. N. Hotta, Diabetes Update, No. 10, Kashikojima Seminar, 19...